Literature DB >> 28476872

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.

Heath D Skinner1, Uma Giri2, Liang P Yang3, Manish Kumar3, Ying Liu3, Michael D Story4, Curtis R Pickering5, Lauren A Byers2, Michelle D Williams6, Jing Wang7, Li Shen7, Suk Y Yoo7, You Hong Fan7, David P Molkentine3, Beth M Beadle8, Raymond E Meyn3, Jeffrey N Myers5, John V Heymach2.   

Abstract

Purpose: The primary cause of death due to head and neck squamous cell carcinoma (HNSCC) is local treatment failure. The goal of this study was to examine this phenomenon using an unbiased approach.Experimental Design: We utilized human papilloma virus (HPV)-negative cell lines rendered radiation-resistant (RR) via repeated exposure to radiation, a panel of HPV-negative HNSCC cell lines and three cohorts of HPV-negative HNSCC tumors (n = 68, 97, and 114) from patients treated with radiotherapy and subjected to genomic, transcriptomic, and proteomic analysis.
Results: RR cell lines exhibited upregulation of several proteins compared with controls, including increased activation of Axl and PI3 kinase signaling as well as increased expression of PD-L1. Additionally, inhibition of either Axl or PI3 kinase led to decreased PD-L1 expression. When clinical samples were subjected to RPPA and mRNA expression analysis, PD-L1 was correlated with both Axl and PI3K signaling as well as dramatically associated with local failure following radiotherapy. This finding was confirmed examining a third cohort using immunohistochemistry. Indeed, tumors with high expression of PD-L1 had failure rates following radiotherapy of 60%, 70%, and 50% compared with 20%, 25%, and 20% in the PD-L1-low expression group (P = 0.01, 1.9 × 10-3, and 9 × 10-4, respectively). This finding remained significant on multivariate analysis in all groups. Additionally, patients with PD-L1 low/CD8+ tumor-infiltrating lymphocytes high had no local failure or death due to disease (P = 5 × 10-4 and P = 4 × 10-4, respectively).Conclusions: Taken together, our data point to a targetable Axl-PI3 kinase-PD-L1 axis that is highly associated with radiation resistance. Clin Cancer Res; 23(11); 2713-22. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28476872      PMCID: PMC5457365          DOI: 10.1158/1078-0432.CCR-16-2586

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

Review 1.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Authors:  Milena P Mak; Pan Tong; Lixia Diao; Robert J Cardnell; Don L Gibbons; William N William; Ferdinandos Skoulidis; Edwin R Parra; Jaime Rodriguez-Canales; Ignacio I Wistuba; John V Heymach; John N Weinstein; Kevin R Coombes; Jing Wang; Lauren Averett Byers
Journal:  Clin Cancer Res       Date:  2015-09-29       Impact factor: 12.531

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

Review 5.  Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia.

Authors:  Delphine Tamara Marie-Egyptienne; Ines Lohse; Richard Peter Hill
Journal:  Cancer Lett       Date:  2012-11-28       Impact factor: 8.679

6.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

7.  Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

Authors:  Paul M Harari; Jonathan Harris; Merrill S Kies; Jeffrey N Myers; Richard C Jordan; Maura L Gillison; Robert L Foote; Mitchell Machtay; Marvin Rotman; Deepak Khuntia; William Straube; Qiang Zhang; Kian Ang
Journal:  J Clin Oncol       Date:  2014-07-07       Impact factor: 44.544

8.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Authors:  Weiyi Peng; Jie Qing Chen; Chengwen Liu; Shruti Malu; Caitlin Creasy; Michael T Tetzlaff; Chunyu Xu; Jodi A McKenzie; Chunlei Zhang; Xiaoxuan Liang; Leila J Williams; Wanleng Deng; Guo Chen; Rina Mbofung; Alexander J Lazar; Carlos A Torres-Cabala; Zachary A Cooper; Pei-Ling Chen; Trang N Tieu; Stefani Spranger; Xiaoxing Yu; Chantale Bernatchez; Marie-Andree Forget; Cara Haymaker; Rodabe Amaria; Jennifer L McQuade; Isabella C Glitza; Tina Cascone; Haiyan S Li; Lawrence N Kwong; Timothy P Heffernan; Jianhua Hu; Roland L Bassett; Marcus W Bosenberg; Scott E Woodman; Willem W Overwijk; Gregory Lizée; Jason Roszik; Thomas F Gajewski; Jennifer A Wargo; Jeffrey E Gershenwald; Laszlo Radvanyi; Michael A Davies; Patrick Hwu
Journal:  Cancer Discov       Date:  2015-12-08       Impact factor: 39.397

9.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  42 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

2.  CXCL11-CXCR3 Axis Mediates Tumor Lymphatic Cross Talk and Inflammation-Induced Tumor, Promoting Pathways in Head and Neck Cancers.

Authors:  Subhashree Kumaravel; Sumeet Singh; Sukanya Roy; Lavanya Venkatasamy; Tori K White; Samiran Sinha; Shannon S Glaser; Stephen H Safe; Sanjukta Chakraborty
Journal:  Am J Pathol       Date:  2020-02-05       Impact factor: 4.307

3.  Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.

Authors:  Hirokazu Sadahiro; Kyung-Don Kang; Justin T Gibson; Mutsuko Minata; Hai Yu; Junfeng Shi; Rishi Chhipa; Zhihong Chen; Songjian Lu; Yannick Simoni; Takuya Furuta; Hemragul Sabit; Suojun Zhang; Soniya Bastola; Shinobu Yamaguchi; Hebaallah Alsheikh; Svetlana Komarova; Jun Wang; Sung-Hak Kim; Dolores Hambardzumyan; Xinghua Lu; Evan W Newell; Biplab DasGupta; Mitsutoshi Nakada; L James Lee; Burt Nabors; Lyse A Norian; Ichiro Nakano
Journal:  Cancer Res       Date:  2018-03-12       Impact factor: 12.701

4.  AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.

Authors:  Nellie K McDaniel; Mari Iida; Kwangok P Nickel; Colin A Longhurst; Samantha R Fischbach; Tamara S Rodems; Carlene A Kranjac; Amber Y Bo; Qianyun Luo; Meghan M Gallagher; Noah B Welke; Kaitlyn R Mitchell; Alison E Schulz; Jaimee C Eckers; Rong Hu; Ravi Salgia; Seungpyo Hong; Justine Y Bruce; Randall J Kimple; Deric L Wheeler
Journal:  Clin Cancer Res       Date:  2020-05-21       Impact factor: 12.531

5.  Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.

Authors:  Mai Badarni; Manu Prasad; Noa Balaban; Jonathan Zorea; Ksenia M Yegodayev; Ben-Zion Joshua; Anat Bahat Dinur; Reidar Grénman; Barak Rotblat; Limor Cohen; Moshe Elkabets
Journal:  JCI Insight       Date:  2019-03-12

6.  Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.

Authors:  Xianzhou Song; Hironari Akasaka; Hua Wang; Reza Abbasgholizadeh; Ji-Hyun Shin; Fenglin Zang; Jiayi Chen; Craig D Logsdon; Anirban Maitra; Andrew J Bean; Huamin Wang
Journal:  J Biol Chem       Date:  2020-01-20       Impact factor: 5.157

7.  Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Mahdi Zargar; Thomas McFarlane; Kelvin K W Chan; William W L Wong
Journal:  Oncologist       Date:  2017-10-11

Review 8.  Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention.

Authors:  Sara M Centuori; Carlos Caulin; Julie E Bauman
Journal:  Curr Treat Options Oncol       Date:  2021-05-15

9.  AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.

Authors:  Irene Tirado-Gonzalez; Arnaud Descot; Devona Soetopo; Aleksandra Nevmerzhitskaya; Alexander Schäffer; Ivan-Maximilano Kur; Ewelina Czlonka; Carolin Wachtel; Ioanna Tsoukala; Luise Müller; Anna-Lena Schäfer; Maresa Weitmann; Petra Dinse; Emily Alberto; Michèle C Buck; Jonathan Jm Landry; Bianka Baying; Julia Slotta-Huspenina; Jenny Roesler; Patrick N Harter; Anne-Sophie Kubasch; Jörn Meinel; Eiman Elwakeel; Elisabeth Strack; Christine Tran Quang; Omar Abdel-Wahab; Marc Schmitz; Andreas Weigert; Tobias Schmid; Uwe Platzbecker; Vladimir Benes; Jacques Ghysdael; Halvard Bonig; Katharina S Götze; Carla V Rothlin; Sourav Ghosh; Hind Medyouf
Journal:  Cancer Discov       Date:  2021-06-08       Impact factor: 39.397

10.  AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.

Authors:  Kavya Ramkumar; C Allison Stewart; Kasey R Cargill; Carminia M Della Corte; Qi Wang; Li Shen; Lixia Diao; Robert J Cardnell; David H Peng; B Leticia Rodriguez; You-Hong Fan; John V Heymach; Jing Wang; Carl M Gay; Don L Gibbons; Lauren A Byers
Journal:  Mol Cancer Res       Date:  2020-11-10       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.